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im Crowe, BS, Samir Kapadia, MD, Steven E. Nissen, MD
leveland, Ohio
OBJECTIVES The aim of this study was to determine the relationship between atheroma regression and
arterial wall remodeling.
BACKGROUND Infusion of reconstituted high-density lipoprotein (rHDL) containing recombinant apoli-
poprotein A-I Milano (AIM) has been reported to promote rapid regression of coronary
atherosclerosis. The current study analyzed intravascular ultrasound (IVUS) to define the
changes that take place in the arterial wall that accompanied atheroma regression in this
study.
METHODS Forty-seven patients, ages 30 to 75 years, after an acute coronary syndrome were randomized
to receive five weekly infusions of placebo or rHDL containing either low- or high-dose
AIM. External elastic membrane (EEM) and lumen volumes were compared between
coronary IVUS studies at baseline and follow-up.
RESULTS In comparison with baseline, infusion of rHDL was associated with a 4.6% reduction in EEM
volume. Lumen volume did not change. In 10-mm arterial subsegments with the greatest
plaque burden at baseline, atheroma volume regressed by 10.9% with a similar reduction in
EEM volume but with no change in lumen size. In contrast, EEM and atheroma volume did
not change in the 10-mm segments containing the least plaque burden. The reduction in
EEM in the most diseased segments was only apparent in subjects who underwent plaque
regression. Reduction in EEM volume correlated with the decreased atheroma volume (r 0.62),
but there was no correlation between change in lumen size and change in plaque volume.
CONCLUSIONS Remodeling of the arterial wall is a focal and heterogeneous process. After infusion of rHDL
containing AIM, regression of coronary atherosclerosis is accompanied by reverse remodeling
of the EEM, resulting in no change in luminal dimensions. (J Am Coll Cardiol 2006;47:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.11.040992–7) © 2006 by the American College of Cardiology Foundation
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rccumulating evidence supports the concept that enhancing
he circulating levels or biologic activity of high-density
ipoprotein cholesterol (HDL-C) might produce important
linical benefits. Recently, a pilot study using intravascular
ltrasound (IVUS) reported that five weekly infusions of a
ynthetic nascent HDL-like particle resulted in regression
f coronary atherosclerosis (1). This therapy (ETC-216)
omprised complexes of phospholipid combined with re-
ombinant human apolipoprotein A-I Milano (AIM). Two
VUS examinations were compared, the first obtained
ithin two weeks after an acute coronary syndrome and the
econd six weeks later. A surprisingly large extent of
theroma regression (4.2%) was observed after this short-
erm therapy.
Little is known, however, about the mechanisms under-
ying regression of atherosclerosis after HDL-enhancing
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005, accepted September 26, 2005.herapies. Because of the ability of IVUS to visualize the
ntire thickness of the vessel wall, this imaging modality
nables assessment of serial changes in the arterial wall
tructure in vivo. Considerable evidence supports the con-
ept that the vessel wall actively responds to atheroma
ccumulation by undergoing alterations in size and struc-
ure. This dynamic process, termed arterial remodeling,
eems to be bidirectional (2). The early stages of atherogen-
sis are typically accompanied by outward expansion of the
xternal elastic membrane (EEM), referred to as expansive
emodeling. Expansion of the EEM has been described as
n adaptive mechanism that maintains lumen size, thereby
ompensating for accumulating atheroma (3). Expansive
emodeling is thought to predominate in early disease
evelopment but might be followed at a later stage by a
radual shrinkage of the EEM, referred to as constrictive
emodeling, resulting in luminal narrowing.
No data exist, however, regarding the extent and direc-
ion of remodeling during regression of atherosclerosis
hen studied systematically throughout an artery. The aim
f the current study was to characterize the remodeling
esponse of the arterial wall during regression produced by
nfusion of ETC-216.
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xperimental protocol. The study protocol of this trial has
een previously reported in detail (1). Briefly, patients aged
0 to 75 years who required coronary angiography for
linical indications within 14 days after an acute coronary
yndrome were considered eligible to participate in the
tudy. Patients were required to have an obstructive lesion in
major epicardial vessel with at least a 20% luminal
iameter stenosis by visual inspection of the angiogram.
urthermore, a target vessel was required to have no more
han a 50% luminal stenosis throughout a segment with a
inimum length of 30mm, defined as the target segment. The
arget vessel must not have undergone percutaneous interven-
ion in the past or at the time of the baseline study. Patients
ere randomized to receive treatment with either placebo
0.9% normal saline) or a low dose (15 mg/kg) or a high dose
45 mg/kg) of ETC-216, a complex of recombinant human
IM/1-palmitoyl-2-oloeyl-sn-glycero-3-phosphocholine.
reatments were administered as an intravenous infusion at
eekly intervals for five doses. Within two weeks of receiv-
ng the final dose, patients underwent repeat IVUS imaging
f the target vessel to allow for comparison of paired
xaminations at the two time points.
nalysis of IVUS images. All pullbacks were analyzed in
he core laboratory by a single operator, blinded to patient
haracteristics. After digitization of the videotape, the origin
f the most distal side-branch was selected as the beginning
oint for analysis. Every 30th image, spaced 0.5 mm apart,
as subsequently analyzed. The final image analyzed was
he most proximal in the sequence before the appearance of
he left main coronary artery or right coronary ostium,
efined as the proximal fiduciary site. As a result, a series of
lices over a pullback of 30 mm to 80 mm in length was
ssessed. Analysis was performed for both baseline and
ollow-up studies with identical landmarks to ensure that
he same segment was compared at the two time points.
Intravascular ultrasound measurements were performed
n accordance with the standards of the American College
f Cardiology and European Society of Cardiology (4). For
ach cross-sectional image, the leading edges of the lumen
nd EEM borders were traced by manual planimetry.
theroma area was calculated as EEM area minus luminal
rea. The total atheroma volume was calculated with the
impson rule as mean atheroma area multiplied by the
ength of pullback in millimeters. Similarly, the total vol-
Abbreviations and Acronyms
AIM  apolipoprotein A-I Milano
EEM  external elastic membrane
ETC-216  phospholipid:apolipoprotein A-I Milano
complexes
HDL-C  high-density lipoprotein cholesterol
IVUS  intravascular ultrasoundmes occupied by the EEM and lumen respectively were walculated using their summated areas. Plaque volumes
ontained within consecutive 10-mm segments of images
ere calculated by summation of the areas of those images
o determine which subsegments contained the most and
east atheroma burden in each pullback at baseline. Seg-
ents spaced 0.5 mm apart were analyzed. Therefore, a
0-mm segment was defined by 21 consecutive measured
egments.
tatistical analysis. All analyses were performed with
PPS 11 for Mac OS X (SPSS Inc., Chicago, Illinois).
ariables are reported as mean values  SD as well as
edian and interquartile ranges. The difference in ather-
ma, EEM, and lumen volumes between baseline and
ollow-up were compared by Wilcoxon signed rank tests.
pearman correlations were employed to determine the
elationships between changes in plaque volume and
hanges in EEM and lumen volumes. A two-sided p value
0.05 was considered to meet statistical significance.
ESULTS
atient characteristics. The baseline characteristics of pa-
ients have been previously presented in detail (1). Of 57
atients who were randomly assigned therapy (placebo n 
2, 15 mg/kg AIM n  23, and 45 mg/kg AIM n  22),
7 completed the study (2 withdrew with an adverse event,
withdrew consent, and 5 had baseline IVUS studies that
ere unsuitable for analysis). There were no significant
ifferences in baseline characteristics between the treatment
roups. For the entire cohort, mean age was 55  9 years
nd weight 87 14 kg; 61% of patients were male and 97%
ere white; 60% of patients were current smokers; 72% had
oncomitant hypertension and 14% were diabetic; and 44%
ad received statin therapy before enrolment. The preceding
linical episode was classified as unstable angina pectoris
72%) in the majority, whereas fewer patients had a recent
pisode of non–ST-segment elevation myocardial infarction
19%) or ST-segment elevation myocardial infarction (9%).
he plasma lipid profile at baseline included total choles-
erol (179  41 mg/dl), low-density lipoprotein cholesterol
117  38 mg/dl), HDL-C (42  8 mg/dl), and triglycer-
des (160  95 mg/dl).
ffect of AIM on arterial volumes. The effect of ETC-216
nfusions on coronary atheroma has been previously re-
orted (1). The effect of treatment on both total EEM and
umen volumes has not been previously reported and are
ummarized in Table 1. Infusion of ETC-216 had no effect
n the total lumen volume (375  204 mm3 at baseline and
66  194 mm3 at follow-up). In contrast, pooled results
or the low-dose and high-dose ETC-216 groups (the
respecified analysis) was associated with a 4.8% reduction
n the total EEM volume at follow-up (629  355 mm3 at
aseline and 599  320 mm3 at follow-up, p  0.03).
ariable response of EEM to infusion. To determine
hether the remodeling response to infusion of ETC-216
as uniform or variable throughout the length of the arterial
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HDL and Reverse Remodeling March 7, 2006:992–7ullback, serial changes in arterial dimensions were assessed
n the 10-mm segments that contained the greatest and least
laque burden at baseline. Segments containing the greatest
mount of atheroma at baseline were characterized by a
eduction in plaque volume of 17.8 mm3 (10.9%), from
63.4  54.3 mm3 at baseline to 145.6  46.9 mm3 at
ollow-up (p  0.0001). The EEM volume was reduced by
9.3 mm3 (5.6%), from 343.8  92.5 mm3 at baseline to
24.5  97.3 mm3 at follow-up (p  0.006). There was no
hange, however, in lumen volume (from 180.1 68.3 mm3 at
aseline to 178.9 76.6 mm3 at follow-up) (Table 2). Within
hese most diseased segments, the change in plaque volume
orrelated with the change in EEM volume (r  0.62, p 
.0001) but not the change in lumen volume (r  0.13, p 
.45) (Fig. 1).
In contrast, in the 10-mm segments containing the least
laque burden at baseline, there was no significant change in
laque volume (69.6  39.4 mm3 and 71.2  45.2 mm3 at
aseline and follow-up, respectively), EEM volume (221.2 
9.9 mm3 and 222.2  105.4 mm3 at baseline and follow-
p, respectively), or lumen volume (151.5  68.7 mm3 and
51.0  66.6 mm3 at baseline and follow-up, respectively)
Table 1. Effect of Infusing Placebo, Combined
or High-Dose AIM on the EEM and Lumen
Intravascular Ultrasound Examinations Perform
Placebo (n 
Baseline
EEM volume (mm3) 429  257
(357) 186–694 (
Lumen volume (mm3) 273  144
(280) 134–382 (
Results expressed as mean values  SD and (median) inte
follow-up studies.
AIM  apolipoprotein A-I Milano; EEM  external el
cholesterol.
able 2. Effect of Infusing ETC-216 (n  36) on the Plaque,
EM, and Lumen Volumes in the 10-mm Segments That
ontained the Greatest and Least Plaque Burden at Baseline
Volume (mm3) Baseline Follow-Up p Value
reatest diseased
segment
Plaque 163.4  54.3 145.6  46.9 0.0001
(164.9) 132–210 (149.7) 120–182
EEM 343.8  92.5 324.5  97.3 0.006
(349.4) 306–397 (315.4) 273–383
Lumen 180.1  68.3 178.9  76.6 0.59
(181.9) 128–216 (162.8) 125–212
east diseased
segment
Plaque 69.6  39.4 71.2  45.2 0.86
(63.9) 37–103 (65.7) 31–112
EEM 221.2  99.9 222.2  105.4 0.94
(219.3) 135–276 (210.4) 128–295
Lumen 151.5  68.7 151.0  66.6 0.99
(127.9) 102–189 (134.4) 97–214
esults expressed as mean values  SD and (median) interquartile ranges.
EEM external elastic membrane; ETC-216 phospholipid:apolipoprotein A-I
ilano complexes.
b
pTable 2). This phenomenon is depicted in Figure 2, which
emonstrates that sites that undergo plaque regression and
hrinkage of the EEM with preservation of luminal dimen-
ions; however, at sites where there is no change in plaque
rea at serial follow-up, there is no change in either the
imensions of the lumen or EEM.
ISCUSSION
he findings of this study demonstrate that, for the first
ime, regression of atherosclerotic plaque after infusion of a
ynthetic HDL is characterized by a concomitant shrinkage
f the EEM. This results in a lumen size that is virtually
nchanged (Fig. 2). These observations suggest an exquis-
L, or rHDL Containing Either Low-Dose
mes Measured on Matched Coronary
t Baseline and After Treatment
Combined rHDL (n  36)
w-Up Baseline Follow-Up
 254 629  355 599  320*
18–542 (578) 328–872 (562) 354–794
 145 375  204 366  194
46–408 (340) 227–508 (348) 244–487
le ranges. *p  0.03 for comparison between baseline and
embrane; rHDL  reconstituted high-density lipoprotein
igure 1. Correlation between the change in plaque volume and the
hange in lumen volume (A) and external elastic membrane (EEM) volume
B) in the 10-mm segments harboring the greatest plaque burden atrHD
Volu
ed a
11)
Follo
424
356) 2
265
238) 1
rquartiaseline after infusion of phospholipid:apolipoprotein A-I Milano com-
lexes (ETC-216).
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March 7, 2006:992–7 HDL and Reverse Remodelingtely sensitive regulatory mechanism that allows maintenance
f a constant lumen size during atherosclerosis regression by a
recisely compensatory reduction in EEM dimensions. This
henomenon is the exact inverse of the remodeling process
riginally described by Glagov et al. (3), who proposed that,
uring the initial stages of atheroma formation, expansion
f the EEM compensated for plaque accumulation, thereby
reventing compromise of the lumen.
These observations provide a potential explanation for an
mportant clinical conundrum. In angiographic studies of
nti-atherosclerotic agents, changes in luminal dimensions
ave been extremely small, typically representing a change
n stenosis severity of only a few percentage points (5–7).
hese same studies, however, demonstrate a much larger
eduction in clinical events after administration of treat-
ents that effectively slowed or reversed atherosclerosis.
ome authorities have attributed the differences in magni-
igure 2. Representative cross-sectional intravascular ultrasound images of
atched arterial segments at baseline (left) and follow-up (right). At sites
hat underwent atheroma regression in response to infusions of reconsti-
uted high-density lipoprotein cholesterol containing recombinant human
polipoprotein A-I Milano (top and middle panels), there was concom-
tant reduction in external elastic membrane (EEM) area with no change
n the lumen size. At sites where there was no change in plaque area
bottom panels), there was no change in either the EEM or lumen.ude of angiographic and clinical benefit to unknown aechanisms, such as changes in atheroma morphology
plaque stabilization). The current study suggests a radically
ifferent possibility. Because reverse remodeling preserves
umen size during regression, large changes in atheroma
olume might appear as only small changes in luminal dimen-
ions. Accordingly, a substantial reduction in atheroma burden
ight occur despite minimal changes in lumen size.
This is further illustrated by subsegmental analyses in the
urrent study. Analysis of the 10-mm arterial segment with
he greatest atheroma burden demonstrated major regres-
ion of disease after administration of an HDL mimetic.
trikingly, in the most diseased subsegment, HDL therapy
emoved nearly 11% of atheroma volume within six weeks
ith virtually no change in luminal dimensions. This effect
s substantially greater than the extent of regression ob-
erved using the same analytical methods after administra-
ion of 80 mg of atorvastatin for 18 months (8). Similarly,
he effect is six-fold larger than that observed after 18
onths of moderate lipid lowering with 40 mg of pravasta-
in in the same study. The magnitude of these changes in
he most diseased segments suggests a high potential for
DL modulating therapies to benefit patients with coro-
ary disease.
The absence of any meaningful change in luminal dimen-
ions during regression of atherosclerosis also has important
mplications for design of studies of HDL-modulating
herapies. Most previous studies of atherosclerosis progres-
ion have used quantitative coronary angiography to assess
isease burden. Angiographic studies assess disease progres-
ion by measuring a projected silhouette of the vessel lumen.
uch methods have proven useful in describing the effects of
ow-density lipoprotein cholesterol-lowering therapies on
oronary atherosclerosis (6,7,9–13); however, the current
tudy suggests that imaging techniques that measure lumi-
al dimension might provide unreliable results if used to
valuate therapies designed to enhance reverse cholesterol
ransport (14). During administration of HDL-enhancing
gents, rapid reverse remodeling might completely compen-
ate for plaque regression, resulting in no change in lumen
ize. It has also been reported that regression of aortic
theroma after chronic statin therapy is similarly accompa-
ied by no change in luminal dimensions when assessed by
agnetic resonance imaging of the arterial wall (15).
Several studies have shown a strong relationship between
he progression of atherosclerosis and clinical outcome
16,17). The current study suggests several potential mech-
nisms underlying the effects of therapies that promote
isease regression on cardiovascular morbidity and mortal-
ty. The majority of acute ischemic events occur in the
etting of a culprit lesion that represent only a mild to
oderate stenosis by angiography (18–20); however, be-
ause of EEM expansion (positive remodeling), the arterial
all can harbor substantial amounts of plaque before the
evelopment of luminal narrowing detectable by angiogra-
hy (21–23). Several studies have demonstrated a strong
ssociation between the extent of positive remodeling (in-
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HDL and Reverse Remodeling March 7, 2006:992–7reased EEM area) and an unstable clinical presentation
24–26). Conversely, constrictive remodeling (decrease in
EM area) has been associated with stable angina. The
urrent study suggests an intriguing hypothesis—that re-
ression of atherosclerosis reduces expansive remodeling,
hereby conferring mechanical plaque stability.
In the current study, the conclusion that there is a close
inkage between regression and reverse remodeling is sup-
orted by several observations. Analysis of different subseg-
ents within the arterial pullback permitted examination of
he regional relationships between EEM shrinkage and
laque regression. In segments not undergoing regression,
here was no reverse remodeling, whereas in segments with
eduction in atheroma volume, there was a compensatory
eduction in EEM volume. In minimally diseased segments,
egression did not occur and there was virtually no change in
theroma volume, lumen volume, and EEM volume. These
nding emphasize that the compensatory changes associ-
ted with plaque regression represent a focal phenomenon,
ot a generalized response to the therapy or a patient-
pecific response. The exact signaling mechanism by which
everse remodeling is initiated remain undefined, but some
tudies suggest that coronary shear stress might represent an
mportant factor (27,28).
Previously, remodeling of the vessel wall has been con-
idered a gradual adaptive process that occurred during
any years of atherosclerosis development (3). The current
tudy demonstrates that changes in EEM area in response
o regression can occur in only a few weeks. These findings
lso suggest that remodeling is a heterogeneous process
hroughout the course of an artery. The demonstration that
erial arterial remodeling is not homogeneous highlights the
dvantage of performing volumetric analysis of the entire
rtery. This approach provides a more accurate reflection of
ynamic changes in the arterial wall than assessment of
ndividual cross-sectional images.
The study has several important limitations, including the
mall sample size in the active treatment group and few
lacebo-treated patients. Intravascular ultrasound is limited
n its ability to characterize plaque composition, and there-
ore it remains to be determined whether infusing synthetic
DL containing AIM in humans has beneficial effects on
laque in addition to promoting regression. Although it is
heoretically possible that the results were influenced by
egression to the mean, the absence of corresponding
hanges in segments containing the least amount of athero-
clerotic plaque makes this possibility remote. Nonetheless,
he study provides strong evidence that significant regres-
ion of atherosclerosis can occur without any change in
umen size after administration of a synthetic HDL-
imetic based on AIM to patients after an acute coronary
yndrome. Evaluation of new therapies that promote reverse
holesterol transport might require application of methods
hat image the vessel wall, such as IVUS, carotid ultrasound,
r magnetic resonance imaging, rather than methods that
epict the vessel lumen such as quantitative coronary an-iography. These findings further highlight the dynamic
ole that the arterial wall plays in the progression and
egression of atherosclerotic plaque. Changes in EEM area
an occur in only a few weeks when a particularly active
herapy is administered. Arterial remodeling is clearly a
ocal phenomenon, not a generalized response to the sys-
emic factors associated with atherosclerosis progression or
egression.
eprint requests and correspondence: Dr. Steven E. Nissen,
epartment of Cardiovascular Medicine/F15, Cleveland Clinic
oundation, 9500 Euclid Avenue, Cleveland, Ohio 44195.
-mail: nissens@ccf.org.
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